Form 4: Ultragenyx Executive Crombez Reports Stock Transactions

EVP and Chief Medical Officer Eric Crombez reports acquisition and disposal of Ultragenyx Pharmaceutical Inc. stock and stock options.

Summary

• Eric Crombez, EVP and Chief Medical Officer of Ultragenyx Pharmaceutical Inc., filed a Form 4 detailing changes in beneficial ownership.
• On March 1, 2024, Crombez acquired 19,400 shares of common stock through the award of Restricted Stock Units (RSUs) and disposed of 1,238 shares to cover tax withholdings at a price of $53.76 per share.
• He also acquired options to purchase 34,200 shares at $53.69 and 2,351 shares at $67.37.
• Following these transactions, Crombez beneficially owns 48,927 shares of common stock and options to purchase 36,551 shares.
• The RSUs vest in equal installments over four years from the grant date, and the options vest based on time and performance criteria.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of RSUs and options indicates confidence, while the sale of shares for tax purposes is a normal occurrence.

Positives

• The acquisition of RSUs and stock options suggests confidence in the company's future performance.

Negatives

• The sale of shares to cover tax obligations, while common, slightly reduces Crombez's direct holdings.

Risks

• Vesting of RSUs and options is contingent on continued employment and, in some cases, performance criteria, which introduces some risk.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules for RSUs and options suggest a multi-year commitment from the executive.

Industry Context

Executive stock transactions are common in the pharmaceutical industry and are often tied to performance and retention. These transactions provide insight into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the pharmaceutical industry to align management's interests with those of shareholders.
• Vesting schedules of four years for RSUs and performance-based vesting for options are typical in the industry, similar to companies like Amgen, Biogen, and Vertex Pharmaceuticals.
• The size of the stock option grants and RSU awards is within the typical range for executives at companies of Ultragenyx's size and market capitalization.

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment, reflecting executive confidence.
• Employees may view the executive's stock ownership as a positive sign for the company's future.

Key Dates